Key indicators: single-crystal X-ray study; T = 123 K; mean (C-C) = 0.003 Å; R factor = 0.055; wR factor = 0.163; data-to-parameter ratio = 25.6.
In the title compound, C 27 H 29 N 5 O 6 SÁH 2 O {systematic name: 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide monohydrate], the dihedral angle between the mean planes of the pyrimidine rings is 27.0 (1) . The dihedral angle between the mean planes of the benzene rings is 47.7 (8) , forming a Ushaped channel around the chain of twisted pyrimidine rings. The crystal packing is stabilized by O-HÁ Á ÁO, O-HÁ Á ÁN and N-HÁ Á ÁO hydrogen bonds with a single water molecule, and weak O-HÁ Á ÁN intermolecular interactions between the hydroxy group and one of the pyrimidine rings producing an two-dimensional supramolecular array in the bc plane. The title compound studied was a merohedral twin with the major component being approximately 57%.
Related literature
For reviews of bosentan in the management of pulmonary arterial hypertension and systemic sclerosis, see: Gabbay et al. (2007) ; Kumar et al. (2011); Oldfield & Lyseng-Williamson (2006) . For related structures, see: Singh et al. (1985) ; ElGhamry et al. (2008) ; Kant et al. (2012) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). 
yl]benzene-1-sulfonamide) is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH). Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. A review of bosentan in the management of pulmonary arterial hypertension is published (Gabbay et al., 2007) . Another review on the use of bosentan in pulmonary arterial hypertension and systemic sclerosis is also published (Oldfield & Lyseng-Williamson, 2006) . A spectrophotometric method for the determination of bosentan monohydrate in bulk and pharmaceutical dosage forms is reported (Kumar et al., 2011) . The crystal structures of some related compounds, viz., N1-(2,6-dimethyl-4-pyrimidinyl)sulphanilamide (Singh et al., 1985) , et al., 2008) and N-(2-{[5-bromo-2-(morpholin-4-yl)pyrimidin-4-yl]sulfanyl}-4-methoxyphenyl)-4-methyl benzenesulfonamide (Kant et al., 2012) , have been reported. In view of the importance of the title compound, (I), the paper reports its crystal structure.
In (I), the dihedral angle between the mean planes of the two pyrimidine rings is 27.0 (1)° ( material for publication: SHELXTL (Sheldrick, 2008) .
Figure 1
Molecular structure of the title compound showing the atom labeling scheme and 30% probability displacement ellipsoids. The dashed indicates N1-H1···O1W hydrogen bonding within the asymmetric unit. 
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide monohydrate
Crystal data Special details Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger. 0.0211 (7) 0.0189 (7) 0.0209 (7) 0.0013 (6) 0.0060 (6) 0.0008 (6) N3 0.0213 (7) 0.0196 (7) 0.0174 (7) 0.0011 (6) 0.0050 (6) 0.0005 (6) N4 0.0250 (7) 0.0230 (8) 0.0211 (7) 0.0019 (6) 0.0056 (6) 0.0018 (6) N5 0.0216 (7) 0.0201 (7) 0.0238 (7) 0.0004 (6) 0.0055 (6) −0.0004 (6) C1 0.0250 (8) 0.0220 (9) 0.0244 (9) 0.0010 (7) 0.0082 (7) 0.0005 (7 
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